Share
Did you like reading this story? Click the heart to show your love.
117
Latest News

Chairman and CEO Alex Gorsky Discusses Johnson & Johnson's Response to COVID-19 at the Fortune Brainstorm Health Conference

Share
Did you like reading this story? Click the heart to show your love.
117
Watch a video of Gorsky's interview at the virtual summit, which includes the latest information on the company's pursuit of a potential COVID-19 vaccine.
Today's Top Reads Close

As a former U.S. Army Captain, Alex Gorsky knows how to lead a battle. And right now, the Johnson & Johnson Chairman and CEO, alongside employees across the globe, is hard at work innovating solutions in the battle against COVID-19.

Innovations like a potential COVID-19 vaccine, which the company started working on in January. In June, Johnson & Johnson announced it was accelerating the initiation of the Phase 1/2a human clinical trial for its investigational vaccine candidate.

Yesterday, Gorsky appeared as a featured speaker at the annual Fortune Brainstorm Health conference, which focused this year on what we've learned from the COVID-19 pandemic, how we can weather the continuing storm—and prepare for the next.

Watch his interview with conference co-chair David Agus, M.D., Founding Director and CEO of the Lawrence J. Ellison Institute for Transformative Medicine at the University of Southern California, in the video below.

Gorsky discussed Johnson & Johnson's response to the pandemic, the company's rapid progress toward advancing a vaccine—and how COVID-19 has affected virtually every aspect of health and medical care.

"Hopefully some of the lessons we’re learning now in working with different entities can lead to the kind of collaborations we continue in the future," Gorsky says. "That could be one of the silver linings in the long term that the industry and healthcare systems take away."

Video courtesy of FORTUNE

Did you like reading this story? Click the heart to show your love.
117
The video series, hosted by journalist and author Lisa Ling, delves into efforts to create a potential COVID-19 vaccine.

More from Johnson & Johnson

This site uses cookies as described in our Cookie Policy. Please click the "Accept" button or continue to use our site if you agree to our use of cookies.
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue